Late, but not early, inhibition of soluble guanylate cyclase decreases mortality in a rat sepsis model

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 3, 2009, Pages 991-999

  Fernandes, Daniel ^a   Sordi, Regina ^a   Pacheco, Letícia Kramer ^a   Nardi, Geisson Marcos ^c   Heckert, Bettina Tomio ^a   Villela, Christina Gaspar ^d   Lobo, Amanda Revoredo ^d   Barja Fidalgo, Christina ^d   Assreuy, Jamil ^a,b  

^a STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSIDADE DO OESTE DE SANTA CATARINA   (Brazil)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CREATININE; CYCLIC GMP; GUANYLATE CYCLASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTIC ACID; MESSENGER RNA; METHYLENE BLUE; NITROPRUSSIDE SODIUM; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HYPOTENSION; LACTATE BLOOD LEVEL; LUNG; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEPSIS; SURVIVAL; UREA BLOOD LEVEL;

ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CECUM; CYCLIC GMP; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GUANYLATE CYCLASE; METHYLENE BLUE; MORTALITY; OXADIAZOLES; QUINOXALINES; RATS; RATS, WISTAR; RNA, MESSENGER; SEPSIS; VASOCONSTRICTION;

EID: 62449286323     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142034     Document Type: Article

References (43)

1. Andresen M, Dougnac A, Díaz O, Hernández G, Castillo L, Bugedo G, Alvarez M, and Dagnino J (1998) Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care 13:164-168.
2. Assreuy J (2006) Nitric oxide and cardiovascular dysfunction in sepsis. Endocr Metab Immune Disord Drug Targets 6:165-173.
3. Bonde MM, Sheikh SP, and Hansen JL (2006) Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 6:7-16.
4. Buras JA, Holzmann B, and Sitkovsky M (2005) Animal models of sepsis: settingthe stage. Nat Rev Drug Discov 4:854-865.
5. Cauwels A, Van Molle W, Janssen B, Everaerdt B, Huang P, Fiers W, and Brouckaert P (2000) Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity 13:223-231.
6. Cheng X and Pang CC (1998) Pressor and vasoconstrictor effects of methylene blue in endotoxaemic rats. Naunyn Schmiedeberg's Arch Pharmacol 357:648-653.
7. Chin-Wei C, Tostes RC, and Webb RC (2008) P2X7 receptor activation amplifies lipopolysaccharide-induced vascular hyporeactivity via interleukin-1 beta release. J Pharmacol Exp Ther 326:864-870.
8. Cohen RI, Wilson D, and Liu SF (2006) Nitric oxide modifies the sarcoplasmic reticular calcium release channel in endotoxemia by both guanosine-3′,5′ (cyclic) phosphate-dependent and independent pathways. Crit Care Med 34:173-181.
9. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, van Kamp GJ, Bronsveld W, and Thijs LG (1995) Methylene blue increases myocardial function in septic shock. Crit Care Med 23:1363-1370.
10. da Silva-Santos JE, Terluk MR, and Assreuy J (2002) Differential involvement of guanylate cyclase and potassium channels in nitric oxide-induced hyporesponsiveness to phenylephrine in endotoxemic rats. Shock 17:70-76.
11. Donati A, Conti G, Loggi S, Münch C, Coltrinari R, Pelaia P, Pietropaoli P, and Preiser JC (2002) Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med 30:2271-2277.
12. Donati A and Preiser JC (2006) Methylene blue: An old-timer or a compound ready for revival. Crit Care Med 34:2862-2863.
13. Fernandes D, da Silva-Santos JE, Duma D, Villela CG, Barja-Fidalgo C, and Assreuy J (2006) Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity. Mol Pharmacol 69:983-990.
14. FilippovG,BlochDB,andBlochKD(1997)NitricoxidedecreasesstabilityofmRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 100:942-948.
15. Gachot B, Bedos JP, Veber B, Wolff M, and Regnier B (1995) Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med 21:1027-1031.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
17. Keaney JF Jr, Puyana JC, Francis S, Loscalzo JF, Stamler JS, and Loscalzo J (1994) Methylene blue reverses lipopolysaccharide-induced hypotension. Circ Res 74:1121-1125.
18. Li D, Laubach VE, and Johns RA (2001) Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am J Physiol Lung Cell Mol Physiol 281:L369-L376.
19. López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, et al. (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32:21-30.
20. Mac Queen J and Plaut D (1979) Colorimetric microdetermination of plasma lactate. Am J Med Technol 45:34-37.
21. Mayer B, Brunner F, and Schmidt K (1993) Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 45:367-374.
22. Memis D, Karamanlioglu B, Yuksel M, Gemlik I, and Pamukcu Z (2002) The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 30:755-762.
23. Nakane M, Arai K, Saheki S, Kuno T, Buechler W, and Murad F (1990) Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung. J Biol Chem 265:16841-16845.
24. Nathan C (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051-3064.
25. Niu J, Azfer A, and Kolattukudy PE (2008) Protection against lipopolysaccharide- induced myocardial dysfunction in mice by cardiac-specific expression of soluble Fas. JMol Cell Cardiol 44:160-169.
26. Okamoto I, Abe M, Shibata K, Shimizu N, Sakata N, Katsuragi T, and Tanaka K (2000) Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal ligation and puncture. Am J Respir Crit Care Med 162:716-722.
27. Paya D, Gray GA, and Stoclet JC (1993) Effects ofmethylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J Cardiovasc Pharmacol 21:926 -930.
28. Peter C, Hongwan D, Küpfer A, and Lauterburg BH (2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur JClin Pharmacol 56:247-250.
29. Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, Kahn RJ, and Vincent JL (1995) Methylene blue administration in septic shock: a clinical trial. Crit Care Med 23:259 -264.
30. Pyriochou A and Papapetropoulos A (2005) Soluble guanylyl cyclase: more secrets revealed. Cell Signal 17:407-413.
31. Rees DD, Palmer RM, Schulz R, Hodson HF, and Moncada S (1990) Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101:746-752.
32. Sager G (2004) Cyclic GMP transporters. Neurochem Int 45:865-873.
33. Schneider F (1995) Methylene blue infusion in septic shock. Crit Care Med 23:1935-1936; author reply 1938.
34. Schneider F, Lutun P, Hasselmann M, Stoclet JC, and Tempé JD (1992) Methylene blue increases systemic vascular resistance in human septic shock: preliminary observations. Intensive Care Med 18:309 -311.
35. Schrammel A, Behrends S, Schmidt K, Koesling D, and Mayer B (1996) Characterization of 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50:1-5.
36. + channels. Biochim Biophys Acta 1285:123-126.
37. Takata M, Filippov G, Liu H, Ichinose F, Janssens S, Bloch DB, and Bloch KD (2001) Cytokines decrease sGC in pulmonary artery smooth muscle cells via NO- dependent and NO-independent mechanisms. Am J Physiol Lung Cell Mol Physiol 280:L272-L278.
38. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, and Payen D (2006) Sepsis in European intensive care units:results of the SOAP study. Crit Care Med 34:344-353.
39. Wainwright M and Crossley KB (2002) Methylene Blue-a therapeutic dye for all seasons? J Chemother 14:431-443.
40. Weingartner R, Oliveira E, Oliveira ES, Sant'Anna UL, Oliveira RP, Azambuja LA, and FriedmanG(1999) Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res 32:1505-1513.
41. Wichterman KA, Baue AE, and Chaudry IH (1980) Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res 29:189-201.
42. Zacharowski K, Berkels R, Olbrich A, Chatterjee PK, Cuzzocrea S, Foster SJ, and Thiemermann C (2001) The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models ofGram-positive and Gram-negative shock. Crit Care Med 29:1599-1608.
43. Zhang H, Rogiers P, Friedman G, Preiser JC, Spapen H, Buurman WA, and Vincent JL (1996) Effects of nitric oxide donor SIN-1 on oxygen availability and regional blood flow during endotoxic shock. Arch Surg 131:767-774.